ALKERMES | ALKS - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
ALKERMES USD 167.54M 1.08M 2026-06
Amgen USD 541M 1000K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
J&J USD 2.41B 1.35M 2026-03
Malin Corporation EUR 200K 0 2024-12
Merck USD 2.47B 4.93M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Otsuka Holdings JPY 525.39M 1.91M 2026-06
Ovoca Bio EUR 29.49M 0 2025-12
Pfizer USD 5.7B 0 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06